Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $287.3 million.

  • Whitehawk Therapeutics' Cash & Current Investments rose 35875.21% to $287.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $287.3 million, marking a year-over-year increase of 35875.21%. This contributed to the annual value of $47.2 million for FY2024, which is 5660.16% down from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Cash & Current Investments is $287.3 million, which was up 35875.21% from $209.5 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Cash & Current Investments peaked at $287.3 million during Q3 2025, and registered a low of $36.8 million during Q2 2021.
  • For the 5-year period, Whitehawk Therapeutics' Cash & Current Investments averaged around $132.1 million, with its median value being $129.8 million (2022).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 5660.16% in 2024, then surged by 35875.21% in 2025.
  • Whitehawk Therapeutics' Cash & Current Investments (Quarter) stood at $149.0 million in 2021, then rose by 15.82% to $172.6 million in 2022, then tumbled by 36.92% to $108.8 million in 2023, then tumbled by 56.6% to $47.2 million in 2024, then surged by 508.14% to $287.3 million in 2025.
  • Its Cash & Current Investments was $287.3 million in Q3 2025, compared to $209.5 million in Q2 2025 and $231.1 million in Q1 2025.